The trend is boosting demand for whey protein concentrates and isolates used in sports nutrition, meal replacements, functional beverages, and medical nutrition products. Market participants say the rapid expansion of GLP-1 drug usage is reshaping purchasing patterns throughout the food and dairy supply chain, tightening availability of premium protein ingredients.

Industry analysts note that whey, once considered a lower-value byproduct of cheese production, has evolved into one of the dairy sector’s most strategically valuable commodities. Manufacturers are now competing to secure whey supplies as processors adapt production strategies to capture higher-margin opportunities in health and wellness categories.

The shift is also influencing dairy trade flows and investment decisions. Companies are increasing capacity for whey processing and filtration technologies while monitoring whether current demand growth can be sustained long term. Analysts warn that supply constraints may persist if consumer adoption of GLP-1 medications continues to rise globally.